The focal amplifications of MYC occur most frequently in ovarian serous cystadenocarcinoma (64.8%), followed by esophageal carcinoma (45.3%), lung squamous cell carcinoma (37.2%), uterine carcinosarcoma, and bladder urothelial carcinoma [4]. Here, MYC is linked to uterine carcinosarcoma.